Myelofibrosis Treatment Market by Type (Targeted therapy, Chemotherapy and Others), Distribution Channel (Hospital pharmacies, Retail and specialty pharmacies and Online pharmacies) and Geography (North America, Europe, APAC and RoW)-Forecast up to 2023 - 2028
Myelofibrosis Treatment Market is expected to be around 900 Million by 2028 at a rate of 4.2% CAGR by 2028.
COVID-19 Impact Analysis Report
Infopedia: Access Our All Reports Online at Affordable Price
CLICK HEREREPORT DESCRIPTION
Myelofibrosis is an unusual type of blood cancer. The bone marrow becomes scarred, which makes it complicated to make blood cells. It belongs to a group of diseases referred as myeloproliferative disorders or myeloproliferative neoplasms. Stem cells are immature blood-forming cells produced by the bone marrow and can distinguish into red blood cells, white blood cells, or platelets. In myelofibrosis, a DNA alteration (mutation) in a stem cell leads to the cell becoming debilitated or a cancer cell. Factors such as polycythemia vera, thrombocythemia, and exposure to industrial chemicals and high levels of radiation can increase the risk of myelofibrosis. As a result, the increasing incidence of these risk factors among a vital part of the population acts as one of the major factors compelling the market growth. In addition, as primary myelofibrosis is the highly diagnosed disease among people of 50 years and above, the increasing old population and enhancing diagnostic modalities are positively influencing the demand for myelofibrosis treatment methods across the world. On the other hand, the uncertainty in diagnosis of myelofibrosis symptoms limits the market growth. The Myelofibrosis Treatment Market is expected to be around 900 Million by 2028 at a rate of 4.2% CAGR by 2028.
The Myelofibrosis Treatment Market has been segmented below:
Myelofibrosis Treatment Market on the basis of Type
Myelofibrosis Treatment Market on the basis of Distribution Channel
Myelofibrosis Treatment Market on the basis of Geography
In the market for type, the myelofibrosis treatment market is segmented into Targeted therapy, Chemotherapy and Others. Among them the chemotherapy segment is likely to hold the significant share in the market. This is due to the increasing prevalence of cancer among mass. Moreover, the rise in the healthcare expenditure is also leading to the segment growth. Governments are also contributing to develop healthcare infrastructure by raising government funds available to the industry, and this will further impel the segment growth. Moreover, the market chemotherapy products will further driven by expansion of developing nations.
As per the myelofibrosis treatment market by distribution channel, the market is categorized into Hospital pharmacies, Retail and specialty pharmacies and Online pharmacies. The Retail and specialty pharmacies segment is anticipated to have the largest share in the myelofibrosis treatment market. The largest share of the segment is attributed to the easy availability of drugs.
In terms of geography, the myelofibrosis treatment market is divided into North America, Europe, Asia Pacific and Rest of the World. North America region has acquired the maximum share in the agricultural packaging market. This is owing to the presence of major market competitors such as Incyte Corporation, Amneal Pharmaceuticals, Inc, Actuate Therapeutics Inc., AbbVie Inc, Pfizer Inc. and Imago BioSciences and improvement in research of development of cancer drugs in the region fuel the growth of the market. In addition to this, the rise in соnсеrn аmоng реорlе for mаіntаіnіng а healthy lifestyle and consistent growth in thе old population, in the region, this is anticipated to augment growth of the market.
Globally, the healthcare expenditure is rising which is projected to propel the demand for effective treatments for myelofibrosis eventually contributes to the global growth of the myelofibrosis treatment market. In addition to this, the governments across the world are taking initiatives to enhance the access to healthcare and support research and development in the domain of myelofibrosis treatment.
Significant competitors of the myelofibrosis treatment market are Bristol-Myers Squibb Company, Actuate Therapeutics Inc., CTI BioPharma Corp, Incyte Corporation, Amneal Pharmaceuticals, Inc., AbbVie Inc., GlaxoSmithKline plc, Pfizer Inc., Imago BioSciences, and Galecto, Inc.
As a result, the myelofibrosis treatment is expected to witness a significant scope in the future period. This is because; the healthcare research and development organizations are taking significant initiatives to develop various advanced treatments for the rare blood cancer.
1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Type: Market Size & Analysis
5.1. Overview
5.2. Targeted therapy
5.3. Chemotherapy
5.4. Others
6. Distribution Channel: Market Size & Analysis
6.1. Overview
6.2. Hospital pharmacies
6.3. Retail and specialty pharmacies
6.4. Online pharmacies
7. Geography: Market Size & Analysis
7.1. Overview
7.2. North America
7.3. Europe
7.4. Asia Pacific
7.5. Rest of the World
8. Competitive Landscape
8.1. Competitor Comparison Analysis
8.2. Market Developments
8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
8.2.2. Product Launches and execution
9. Vendor Profiles
9.1. Bristol-Myers Squibb Company
9.1.1. Overview
9.1.2. Financial Overview
9.1.3. Product Offerings
9.1.4. Developments
9.1.5. Business Strategy
9.2. Actuate Therapeutics Inc.
9.2.1. Overview
9.2.2. Financial Overview
9.2.3. Product Offerings
9.2.4. Developments
9.2.5. Business Strategy
9.3. CTI BioPharma Corp
9.3.1. Overview
9.3.2. Financial Overview
9.3.3. Product Offerings
9.3.4. Developments
9.3.5. Business Strategy
9.4. Incyte Corporation
9.4.1. Overview
9.4.2. Financial Overview
9.4.3. Product Offerings
9.4.4. Developments
9.4.5. Business Strategy
9.5. Amneal Pharmaceuticals, Inc.
9.5.1. Overview
9.5.2. Financial Overview
9.5.3. Product Offerings
9.5.4. Developments
9.5.5. Business Strategy
9.6. AbbVie Inc.
9.6.1. Overview
9.6.2. Financial Overview
9.6.3. Product Offerings
9.6.4. Developments
9.6.5. Business Strategy
9.7. GlaxoSmithKline plc
9.7.1. Overview
9.7.2. Financial Overview
9.7.3. Product Offerings
9.7.4. Developments
9.7.5. Business Strategy
9.8. Pfizer Inc.
9.8.1. Overview
9.8.2. Financial Overview
9.8.3. Product Offerings
9.8.4. Developments
9.8.5. Business Strategy
9.9. Imago BioSciences
9.9.1. Overview
9.9.2. Financial Overview
9.9.3. Product Offerings
9.9.4. Developments
9.9.5. Business Strategy
9.10. Galecto, Inc
9.10.1. Overview
9.10.2. Financial Overview
9.10.3. Product Offerings
9.10.4. Developments
9.10.5. Business Strategy
10. Analyst Opinion
11. Annexure
11.1. Report Scope
11.2. Market Definitions
11.3. Research Methodology
11.3.1. Data Collation and In-house Estimation
11.3.2. Market Triangulation
11.3.3. Forecasting
11.4. Report Assumptions
11.5. Declarations
11.6. Stakeholders
11.7. Abbreviations
The Myelofibrosis Treatment Market has been segmented below:
Myelofibrosis Treatment Market on the basis of Type
Myelofibrosis Treatment Market on the basis of Distribution Channel
Myelofibrosis Treatment Market on the basis of Geography
© 2020 COPYRIGHT : MARKET RESEARCH ENGINE